Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corp on December 4, 2012, covering events occurring on November 28, 2012, and December 3, 2012. The filing primarily addresses significant changes in executive leadership and the execution of new employment agreements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation:
- Thomas Bocchino (CFO): Base salary of $200,000 annually; signing bonus of options to purchase 1,000,000 shares of common stock.
- Dr. Phillip P. Chan (CEO): Base salary of $231,496 annually.
- Vincent Capponi (COO): Base salary of $219,674 annually.
Material Changes
The primary material change reported is the appointment of Thomas Bocchino as Chief Financial Officer and Vice President of Finance, effective November 28, 2012. Additionally, the Company renewed employment agreements with CEO Dr. Phillip P. Chan and COO Vincent Capponi, retroactively effective as of January 1, 2012.
Outlook, Risks, and Unusual Items
Management Commentary: Mr. Bocchino brings over 25 years of financial and operational experience, including previous CFO roles at New Brunswick Scientific Co., Inc. and IVC Industries, Inc.
Contract Terms:
- Mr. Bocchino's agreement expires on December 31, 2013. His stock options vest over two years and expire on November 28, 2017.
- Dr. Chan and Mr. Capponi have one-year employment terms.
- All agreements include non-disclosure provisions and a one-year non-compete clause following separation.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 1,000,000 stock options granted to Thomas Bocchino.
- Review the full text of the employment agreements filed as Exhibits 10.1, 10.2, and 10.3 for additional compensation clauses or termination provisions.
- Confirm the impact of the new CFO appointment on the Company's financial reporting and operational strategy.
- Check for any subsequent filings regarding the Company's financial status, as this 8-K contains no financial performance data.